Axitinib Tablets — Competitive Intelligence Brief

Axitinib Tablets (Axitinib Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

phase 1 tyrosine kinase inhibitor VEGFR-1, VEGFR-2, VEGFR-3 Oncology Small molecule

Target snapshot

Axitinib Tablets (Axitinib Tablets) — Nanjing Leads Biolabs Co.,Ltd. Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Axitinib Tablets TARGET	Axitinib Tablets	Nanjing Leads Biolabs Co.,Ltd	phase 1	tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3
PAZOPANIB HYDROCHLORIDE	PAZOPANIB HYDROCHLORIDE		marketed		VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	GWT-TUD GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Sitravatinib	sitravatinib	Pfizer	marketed	Tyrosine kinase inhibitor	Tyrosine kinases
Sequential Icotinib Plus Chemotherapy	Sequential Icotinib Plus Chemotherapy	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

1. Centre Leon Berard · 2 drugs in this class
2. Akeso · 1 drug in this class
3. Astex Pharmaceuticals, Inc. · 1 drug in this class
4. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
7. Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
8. Ocular Therapeutix, Inc. · 1 drug in this class
9. Peking University Cancer Hospital & Institute · 1 drug in this class
10. Pfizer · 1 drug in this class